title: Perspectives in Engineered Mesenchymal Stem/Stromal Cells Based Anti- Cancer Drug Delivery Systems.
abstract: Understanding and apprehension of the characteristics and circumstances in which mesenchymal stem cells (MSCs) affect and make alterations (enhance or reduce) to the growth of tumors and metastasis spread is pivotal, not only for reaching the possibility to employ MSCs as drug delivery systems, but also for making forward movement in the existing knowledge of involvement of major factors (tumor microenvironment, soluble signaling molecules, etc.) in the process of carcinogenesis. This capability is reliable because MSCs present a great basis for engineering and constructions of new systems to target cancers, intended to secrete therapeutic proteins in the tumor region, or for delivering of oncolytic viruses' directly at the tumor site (targeted chemotherapy with enzyme prodrug conversion or induction of tumor cell apoptosis). MSCs as a crucial segment of the tumor surroundings and their confirmed tumor tropism, are assumed to be an open gateway for the design of promising drug delivery systems. The presented paper reviews current publications in this fieldwork, searches out the most recent patents that were published after 2012 (WO2014066122, US20140017787, WO2015100268, US20150086515), and tries to present the current progress and future prospective on the design and development in anti-cancer drug delivery systems based on MSCs.
authors.forename: Darinka Gjorgieva
authors.initials: DG
authors.lastname: Ackova
authors.forename: Tatjana
authors.initials: T
authors.lastname: Kanjevac
authors.forename: Lia
authors.initials: L
authors.lastname: Rimondini
authors.affiliation: Faculty of Medical Sciences, University "Goce Delcev" Stip, Krste Misirkov bb, 2000 Stip, R. Macedonia. darko.bosnakovski@ugd.edu.mk.
authors.forename: Darko
authors.initials: D
authors.lastname: Bosnakovski
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000378:metabolism; D001698:Biomedical Engineering / Q000379:methods*; D016503:Drug Delivery Systems / Q000379:methods*; D006801:Humans; D045164:Mesenchymal Stem Cell Transplantation / Q000379:methods*; D059630:Mesenchymal Stem Cells / Q000378:metabolism; D010330:Patents as Topic; D059016:Tumor Microenvironment / Q000187:drug effects / Q000502:physiology
chemical_list: D000970:Antineoplastic Agents